Protective efficacy of BCG against leprosy in São Paulo.
The case-control study reported here evaluated the protective effect of BCG vaccine against leprosy in São Paulo, Brazil. Seventy-eight patients under age 16 who had been diagnosed as having leprosy (cases) and 385 healthy individuals (controls) were selected and matched by sex, age, place of residence, and type of exposure to leprosy (intradomiciliary or extradomiciliary). The cases were drawn from an active patient registry and from a group of new leprosy cases treated at 50 health centers in the cities of Bauru and Ribeirão Preto in the state of São Paulo. In order to estimate the protective effect of BCG, the prevalences of BCG scars in cases and controls were compared. The presence of one or more scars was associated with an estimated protective efficacy of 90% (95% confidence interval: 78% to 96%). Stratified analysis by age group, sex, socioeconomic level, and clinical form of the disease revealed no significant differences in the protection provided by the vaccine. However, it seems clear that more data will be needed in order to accurately assess the true relevance of BCG for leprosy control programs.
Lombardi
C
C
Pan American Health Organization, Brasília, Brazil.
Pedrazzani
E S
ES
Pedrazzani
J C
JC
Filho
P F
PF
Zicker
F
F
D000293:Adolescent; D001500:BCG Vaccine; D001938:Brazil; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007918:Leprosy / Q000517:prevention & control*; D008297:Male; D015995:Prevalence; D012307:Risk Factors; D014504:Urban Health
D001500:BCG Vaccine